

20th JEAN S. MARX Memorial Education Forum

Care of Patients with Chronic Neuromuscular Respiratory Weakness

Beaumont

Nader Mina, MD

Medical Director; Sleep Evaluation Services

Division of Pulmonary, Critical Care, and Sleep Medicine, Beaumont, Royal Oak

Assistant Professor, Department of Internal Medicine

Oakland University William Beaumont School of Medicine

Disclosures



None

Objectives



- Review of respiratory neuroanatomy
- General respiratory issues in neuromuscular disease (NMD)
- Sleep and neuromuscular disease
- Specific Diseases
- Respiratory evaluation of patients with NMD
- Management

Objectives




- Review of respiratory neuroanatomy
- General respiratory issues in neuromuscular disease (NMD)
- Sleep and neuromuscular disease
- Specific Diseases
- Respiratory evaluation of patients with NMD
- Management

Respiratory Neuroanatomy



- CNS
 - -Chemoreceptors, medullary drive centers, spinal cord
- Peripheral Nervous System
 - -Nerve roots, peripheral nerves
- Peripheral Receptors
 - -Chemoreceptors, muscle receptors



Respiratory Neuroanatomy




Muscles of Inspiration

Core Muscles

- External intercostals (contracts to elevate ribs)
- Diaphragm (contracts to expand thoracic cavity)

Accessory Muscles

- Sternocleidomastoid (contracts to elevate sternum)
- Pectoralis minor (contracts to pull ribs outwards)



Muscles of Expiration

Core Muscles


- Internal intercostals (contracts to pull ribs down)
- Diaphragm
 (relaxes to reduce thoracic cavity)

Accessory Muscles

- Abdominals
 (contracts to compress abdomen)
- Quadratus lumborum (contracts to pull ribs down)

Respiratory Neuroanatomy





Objectives



- Review of respiratory neuroanatomy
- General respiratory issues in neuromuscular disease (NMD)
- Sleep and neuromuscular disease
- Specific Diseases
- Respiratory evaluation of patients with NMD
- Management



Weakness of respiratory muscles (inspiratory, expiratory, and upper airway)



Inadequate Ventilation
Nocturnal Hypoventilation
Bulbar Dysfunction
Ineffective Cough



Inadequate Ventilation

- Weakness of inspiratory muscles
- Decrease in tidal Volume
- Increase to respiratory rate (inadequate compensation)
- Rise in PaCO2
- Hypoxemia (Due to hypoventilation and atelectasis)
- Symptoms and signs:
 - Dyspnea, orthopnea
 - Rapid shallow breathing
 - Accessory muscle use



Bulbar Dysfunction

- Impairment of upper airway muscles
- Symptoms and signs:
 - Dysphagia
 - Dysarthria
 - Weak mastication
 - Facial weakness
 - Abnormal secretions clearance
 - Nasal speech
 - Protruding tongue




Ineffective Cough

Weakness of upper airway muscles, inspiratory, and expiratory muscles

- Mechanism of cough:
 - Inspiratory phase => Large rapid tidal volume inspiration
 - Compressive phase => Glottic Closure (by addutor muscles) => increase in positive intrathocic pressure
 - Expiratory phase => Glottic opening => high peak expiratory flow

Respiratory System and Medical Service Company





Objectives



- Review of respiratory neuroanatomy
- General respiratory issues in neuromuscular disease (NMD)
- Sleep and neuromuscular disease
- Specific Diseases
- Respiratory evaluation of patients with NMD
- Management



Physiologic changes in Respiratory System during Sleep

Control of Breathing:

Wake: Behavioral (Cortical Centers)

Metabolic

Sleep: Only Metabolic (PH, PaO₂, PaCO₂)


Reduce ventilatory responses



Physiologic changes in Respiratory System during Sleep

Airways and Respiratory Muscles:

- $\downarrow \downarrow \downarrow$ UA dilator muscle tone => Increase Collapsibility
- ↓↓Activity of accessory muscles of respiration
 => Decrease Minute Ventilation





Summary of Important Physics gic Changes

- Decreas sinute ati 1 54
- Decrease in
- Dec. Respiratory System is
- Increase
 Vulnerable During Sleep
- FRC ss intercostal muscle activit



Changes in patients with NMD


- Weakness of respiratory and chest wall muscles
- Weakness of upper airway muscles => increase airway resistance
- REM- related hypotonia and atonia of all muscles except diaphragm => diaphragmatic overload => Nocturnal Hypoventilation (usually before daytime hypoventilation)
- Kyphoscoliosis => restrictive disease
- Reduced responsiveness of chemoreceptors due to altered afferent input from skeletal muscle spindles



Symptoms and Signs:

- Poor concentration
- Drop in school or work performance
- Nocturnal awakenings
- Morning headaches and fatigue
- Hypersomnolence
- Impaired cognition








Polysomnographic Findings

- Reduced lung volumes when supine => severe desaturations especially in REM sleep
- Hypoventilation with marked CO2 elevation
- Pseudocentral apneas
- Obstructive apnea due to upper airway weakness
- Decreased REM sleep









- Suppression of intercostal muscle activity
- Shift of load to weak diaphragm
- More during phasic REM sleep
- More reduction in chest wall relative to abdominal muscles

"Pseudocentral" Apnea







Objectives



- Review of respiratory neuroanatomy
- General respiratory issues in neuromuscular disease (NMD)
- Sleep and neuromuscular disease
- Specific Diseases
- Respiratory evaluation of patients with NMD
- Management

Specific NMD



- Duchene Muscular Dystrophy (DMD)
- Spinal Muscle Atrophy
- Myotonic Dystrophy
- **♦** ALS

Duchene Muscular Dystrophy (DMD)



- X-linked disorder
- Most common lethal muscular dystrophy
- Average ago of diagnosis 5 years old
- Wheelchair dependent by adolescence
- Dystrophin; a protein complex that connects the cytoskeleton of a muscle fiber to the surrounding extracellular matrix through the cell membrane.
- Mutations in the DMD gene alter reading frame and prevent expression of dystrophin protein => muscle fibers degenerate
- Skeletal, cardiac and respiratory muscles primarily affected

Duchene Muscular Dystrophy (DMD)



Natural disease history

- Loss of ambulation 9-11 yo
- Progressive muscle loss & weakness with eventual loss of arm use
- Restrictive lung disease =>Nocturnal hypercapnia with subsequent diurnal hypercapnia
- Cardiomyopathy
- Death late teens/early adulthood

Spinal Muscle Atrophy (SMA)





Spinal Muscle Atrophy (SMA)



- A neurodegenerative disorder- Autosomal recessive
- Most common genetic cause of death in infants
- 4-10: 100,000 live birth
- Motor neuron disease (degeneration of anterior horn cells in spinal cord and motor nuclei in lower brain stem)
- Progressive muscle weakness and atrophy
- Cognition in unaffected
- Various age of presentation

Spinal Muscle Atrophy (SMA)



- Paucity of spontaneous movement
- Severe proximal muscle weakness and hypotonia
- Frog leg position
- Various degrees of bulbar weakness-weak cry/oropharyngeal control
- Extraocular muscles sparred
- Striking discrepancy between high level of social interaction and lack of motor skills
- Natural history results in progressive muscle loss and wasting, profound respiratory weakness

Myotonic Dystrophy (MD)



- Autosomal Dominant disorder
- Skeletal muscle weakness
- Respiratory muscle weakness (less likely in type 2)
- Sleep disturbance (low orexin level => Daytime hypersomnolence)
- Muscle pain
- Cardiac and endocrine abnormalities
- Cognitive impairment

ALS



- Disease of upper and lower motor neurons
- Most cases are sporadic
- < 5% familial

Clinical symptoms

- Vary Widely
- Respiratory and bulbar muscles are frequently involved
- Hypoventilation is predominant especially during sleep
- NPPV has been showed to improve survival and QOL

Objectives



- Review of respiratory neuroanatomy
- General respiratory issues in neuromuscular disease (NMD)
- Sleep and neuromuscular disease
- Specific Diseases
- Respiratory evaluation of patients with NMD
- Management

Respiratory Evaluation of Patients with NMD



Common Statements & Questions

- I have no breathing problem
- I have no problems sleeping
- I don't cough frequently
- I didn't go to hospital for pneumonia or lung problems Why do I need to see a lung doctor ???

Respiratory Evaluation of Patients with NMD



Timing of respiratory symptoms

Respiratory muscles work at all times

Respiratory muscles risk for improves outcome



- Pulmonary Function Test
- Respiratory Muscle Forces
- Cough Effectiveness
- Sleep Studies
- Arterial Blood Gases
- Chest Radiography




Pulmonary function tests

- No single abnormality is diagnostic
- Diagnosis is based on constellation of abnormalities
- Consider measuring FVC and VC in supine position (>10% reduction than upright position)
- Findings:
 - Restrictive pattern
 - Reduced maximum voluntary ventilation (MVV)
 - Reduced maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP)
 - Normal diffusion in absence of pulmonary parenchymal or vascular disease



	Pr			
	Pred	Actual	%Pred	
SPIROMETRY				
FVC (L)	6.18	1.50	24	
FEV1 (L)	5.12	1.50	29	
FEV1/FVC (%)	84	100	119	
FEV3 (L)		1.50		
FEV3/FVC (%)		100		
FEF 25-75% (L/sec)	5.27	3.86	73	
FEF 75-85% (L/sec)		2.51		
FEF 50% (L/sec)	5.89	4.02	68	
FEF 75% (L/sec)	2.47	3.10	125	
FEF 200-1200 (L/sec)		3.79		
FEF Max (L/sec)	10.77	4.45	41	
Expiratory Time (sec)		6.52		
FIF 50% (L/sec)	5.78	3.58	61	
MEP (cmH2O)	231	33	14	
MIP (cmH2O)	-126	-47	37	





Assess for ineffective cough

- Peak cough flow (PCF)
 <160 L/min =>ineffective cough
 - 160-270 L/min => at risk for respiratory infection
- MEP < 60 cmH₂O suggests ineffective cough
- Expiratory cough flow tracing
- Clinical evaluation



Arterial blood gases to evaluate for daytime hypercapnia

Polysomnography in selected patients to assess for sleep disordered breathing and nocturnal hypoventilation (Don't delay the initiation of NIV if patient meets RAD criteria)

Home Sleep Apnea Test should not be used



Assess the need for ventilatory support

- Marked ABG abnormalities
- Reduced FVC <50% or VC < 15-20 ml/kg or VC < 1 L
- MIP < -30 cmH₂O => high risk for hypercapnia
- MEP < 40 cmH₂O => ineffective cough
- The rule of 20/30/40 (VC/MIP/MEP)

Objectives



- Review of respiratory neuroanatomy
- General respiratory issues in neuromuscular disease (NMD)
- Sleep and neuromuscular disease
- Specific Diseases
- Respiratory evaluation of patients with NMD
- Management



Goals of Management

- Improve and stabilize gas exchange
- Ameliorate symptoms
- Improve sleep quality
- Improve quality of life
- Extend survival



Mechanical
Ventilation (NIV
and Invasive
Ventilation)

• Goals
• Devices
• Monitoring

Cough
Assistance

Secretions
Mobilization



Non-Invasive Ventilation (NIV)

- Prevent or delay progression of chronic respiratory failure
- Prolong survival especially in patients with ALS
 - 92 patient with ALS
 - NIV vs. Standard care (after developing orthopnea, MIP<60%, or hypercapnia)
 - Improved quality of life and median survival of 205 days
 - NIV improves survival and quality of life in patients without severe bulbar dysfunction
 - NIV improves sleep-related symptoms but unlikely survival with severe bulbar symptoms



Effects on Sleep:

	Before NPPV	With NPPV		
RDI	10.5	3.1		
REM RDI	20.5	3.0		
Arousal Index	20.6	10.2		
Light sleep	55%	44%		
Slow-wave sle	ep 24%	34%		
REM-sleep	18%	20%		



Important Considerations

- Bilevel support is the most common type- CPAP is not appropriate in most cases
- Back up rate is often recommended due to frequency of central and pseudocentral apnea
- Volume assured ventilation it theoretically better for progressive disease
- Proper mask interface is essential for successful treatment
- Don't delay NIV for PSG
- In lab PAP titration may not be required in many cases
- Consider desensitization techniques to improve tolerance and adherence
- Home monitoring for therapy



Technical and Practical Aspects

Respiratory Assist Device

Mechanical Ventilator









Respiratory Assist Devices	Mechanical Ventilators
Codes -E0470- Bilevel (S mode) -E0471- Bilevel (ST mode)	Codes -E0464
Features -Light weight -No mandatory alarm -Can be remotely monitored and controlled -Integrated humidity	Features -Heavy -Internal batteries -Can be remotely monitored -Multiple settings (day/night) -Alarms and monitors



CMS Criteria for RAD

I. Restrictive Thoracic Disorders

Documentation of neuromuscular disease or severe thoracic cage abnormality in the patient's medical record

Perform one of the following:

- ABGs (done while awake and on prescribed FiO₂) PaCO₂ ≥ 45 mm Hg or
- Sleep oximetry
 Oxygen saturation ≤ 88% for ≥ 5 minutes, minimum 2 hours of recording time (on patient's prescribed FiO₂) or
- For neuromuscular disease only:
 Either FVC < 50% of predicted or MIP < 60 cm H₂O

COPD does not contribute significantly to pulmonary limitation (E0470) or (E0471)

Based on the treating physician's judgment

E0470 => BPAP- S (without back up Rate)

E0471 => BPAP- S/T or VPAPS



Ventilators with Mask Interface:

Elevated PaCO2 despite the use of RAD

Prolonged use of device (>8-12 hours daily)


High pressure requirement needed for daytime support


Portability is required



S Mode (spontaneous)


ST mode (spontaneous/timed) BIPAP-ST (Respironics) VPAP-ST (ResMed)








ST mode (spontaneous/timed) BIPAP-ST (Respironics) VPAP-ST (ResMed)



T mode (timed)






Volume Assured Pressure Support Modes

AVAPS (AE)	iVAPS (AE)
ST mode (Philips)	ST mode (ResMed)
Back up rate (Fixed or Auto)	Back up rate (intelligent)
Tidal Volume	Alveolar Ventilation (Va)
EPAP (fixed or auto)	EPAP (fixed or auto)
Remote monitoring	Remote monitoring




Volume Assured Modes with Floating EPAP (AVAPS-AE)





Volume Assured with intelligent BUR (iVAPS)





Volume Assured with intelligent BUR (iVAPS)

RR	10	12	15	20	24
Vt (mls)	690	595	500	405	358
MV (I/min)	6.9	7.14	7.5	8.1	8.58
Va (I/min)	5.7	5.7	5.7	5.7	5.7



Editorial

Thorax August 2012 Vol 67 No 8

Target volume settings for home mechanical ventilation: great progress or just a gadget?

Wolfram Windisch, Jan Hendrik Storre

cases patients were already familiar with pressure-preset NPPV prior to randomisation, thus indicating a selection bias. Therefore, the evidence for target volume setting remains inconclusive, and it is yet to be established whether these hybrid modes of ventilation have benefits that are clear and consistent enough to warrant official recommendations.

Murphy and colleagues randomly allocated 50 NPPV-naive patients with severe OHS (body mass index 50±7 kg/m²)



Why do we use VAPS?

- Most labs are not aggressive in initial titration
- Pressure requirements change with progression of disease
- Patient may not have access to in lab titration
- Advancing therapy without lab titration may speed the process and reduce paperwork
- VAPS improved compliance in some studies

Management of Patients Medical Service Company Memorial Education Forum With NMD-NIV

Mask Interface – Full Face Masks



Management of Patients Medical Service Company Medical Service Company Memorial Education Forum

Mask Interface – Nasal Masks










- Reduces aerophagia
- Allows easy oral suctioning
- Easy to call for help
- Reduces claustrophobia



Mouthpiece Ventilation (SIP)








Monitoring of NIV:


- Downloads from devices
- CO2 monitors
- Overnight Oximetry
- ABG
- Monitor for complications



Compliance Report Usage 02/13/2018 - 03/14/2018 Usage days 29/30 days (97%) >= 4 hours 29 days (97%) < 4 hours 0 days (0%) Usage hours 206 hours 38 minutes Average usage (total days) 6 hours 53 minutes Average usage (days used) 7 hours 8 minutes Median usage (days used) 7 hours 20 minutes VPAP ST-A Serial number 22161395802 **IVAPS** Mode Target Alveolar Ventilation (Va) 4.5 L/min EPAP 10 cmH20 Min PS 4 cmH20 Max PS 20 cmH20 Target Patient Rate 18 bpm Therapy Leaks - L/min Median: 0.0 95th percentile: 15.0 Maximum: 44.4 Events per hour AHI: Usage - hours










Jsage days				00.20	/2018 - 04/18			
					30/30 days (1	100%)		
>= 4 hours					30 days (1	100%)	Usage days	30
< 4 hours					0 days	s (0%)	>= 4 hour da	ays
Jsage hours				31	1 hours 39 m	inutes	< 4 hour day Days not use	
Average usage (total day	/s)			1	0 hours 23 m	inutes	Days no data	а
Average usage (days us	ed)			1	0 hours 23 m	inutes	Used/day (av	vg.)
Median usage (days use	d)			1	0 hours 32 m	inutes		
Astral 150: Program	1			5	SN: 2217112	24138		
Device Settings: Program	1							
Mode						IVAPS	Set threshol	d
Circuit					Single wit	th leak	95th % (avg	
Patient Interface						Mask	Median (avg	
Mask					F	Pillows	5th % (avg)	
Patient Type						Adult	AirFit P10 fo Medium	r Her
Height					6	63.0 in		
nspiratory Phase Delivery	Settings: P	rogram 1						
Target alveolar ventilation	n				4	L/min		
Min PS					4 c	mH2O	Mode	
Max PS					20 c	mH2O	Set Max	
Rise time					4	50 ms	Min	
nspiratory Trigger Setting	s: Program	1					EPAP	E
Target patient rate					15 breath	ns/min	95th % (avg) Median (avg)	
Trigger					M	edium	5th % (avg)	
nspiratory Phase Duration	Settings: P	rogram 1						
Ti Min					1	.0 sec		
Ti Max					2	2.2 sec	ані 🗆	
Cycle					2	25.0 %	HI I	
Expiratory Phase Settings:	Program 1						AI 🔳	
EPAP					6 c	mH2O		
Therapy: Program 1								
_eak - L/min	5th %:	1.1	Median:	4.8	95th %:	13.4		






When to consider daytime NIV?

- Elevation of PaCO2 despite adequate treatment at night
- Daytime symptoms of dyspnea
- Frequent pneumonia due to cough insufficiency
 - Mouthpiece ventilator can improve cough

Management of Patients Medical Service Company Medical Service Company Memorial Education Forum


Tracheostomy

- Difficulty clearing secretions
- NIV is no longer sufficient
- Failure to wean off MV after an acute illness
- Discuss goals of care





Neuromuscular Respiratory Failure





Cough Assist Device

Mechanical insufflation-exsufflation








Secretions Mobilization Techniques

- High frequency chest wall oscillation
- Intrapulmonary percussive ventilation



Management of Patients with NMD DMD – Updated guidelines







Thank You